Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp29062_8k.htm |
Exhibit 99.01
|
Press Release
www.shire.com
|
 |
Director/PDMR Share Dealings
February 29, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on February 28, 2012 the following Persons Discharging Managerial Responsibility (“PDMRs”) were granted awards under the Shire Portfolio Share Plan (PSP).
Stock Appreciation Right Awards (“SAR Awards”) under Part A of the PSP
SAR Awards will normally vest after three years, subject to any performance targets having been satisfied. No consideration is payable for these awards.
|
Type of Security 1
|
No of Ordinary Shares/ADSs
|
Exercise price
|
|
|
Angus Russell 2
|
ADSs
|
47,861
|
$105.50
|
|
Graham Hetherington 2
|
Ordinary Shares
|
55,554
|
£22.22
|
|
Michael Cola
|
ADSs
|
9,683
|
$105.50
|
|
Barbara Deptula
|
ADSs
|
5,645
|
$105.50
|
|
Sylvie Gregoire
|
ADSs
|
10,409
|
$105.50
|
|
Tatjana May
|
Ordinary Shares
|
20,180
|
£22.22
|
|
Kevin Rakin
|
ADSs
|
6,778
|
$105.50
|
Performance Share Awards (“PSA Awards”) under Part B of the PSP
PSA Awards will normally vest after three years, subject to any performance targets having been satisfied. No consideration is payable for these awards.
|
Type of Security 1
|
No of Ordinary Shares/ADSs
|
|
|
Angus Russell 2
|
ADSs
|
35,896
|
|
Graham Hetherington 2
|
Ordinary Shares
|
40,740
|
|
Michael Cola
|
ADSs
|
7,101
|
|
Barbara Deptula
|
ADSs
|
4,064
|
|
Sylvie Gregoire
|
ADSs
|
7,633
|
|
Tatjana May
|
Ordinary Shares
|
14,530
|
|
Kevin Rakin
|
ADSs
|
4,971
|
1. One ADS is equal to three Shire ordinary shares.
2. Vesting of awards granted to Executive Directors is subject to performance targets.
This notification is made to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
For further information please contact:
|
Investor Relations
|
Eric Rojas (erojas@shire.com)
|
+1 781 482 0999
|
|
Sarah Elton-Farr (seltonfarr@shire.com)
|
+44 1256 894157
|
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
2